Industry Source Confirms Hong Kong Main Port Of Mainland China Counterfeit Drugs
This article was originally published in PharmAsia News
Executive Summary
Hong Kong remains at the center of the flow of counterfeit drugs from mainland China to other countries, according to a pharmacy industry source in the city. The source said illicit activities are able to move more easily through Hong Kong than other places because it is a free port. Counterfeit drugs on foreign markets, primarily from the Chinese mainland, include those for treating cholesterol, diabetes and heart and liver problems. The Office of the U.S. Trade Representative issued a report last year naming Hong Kong, the Philippines, Thailand, Paraguay and Ukraine as having "significant problems" with smuggled counterfeits. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.